Life Sciences M&A: Private Target Deal Trends
Event summary
Join Cooley and SRS Acquiom for a panel discussion on recent trends on private target deal terms in life sciences M&A.
The discussion will draw on the experience of life sciences leaders, along with SRS Acquiom’s recently released 2019 Life Sciences M&A Study, which analyzes their unique data set of private target M&A transactions in the biotechnology, medical device, and diagnostics and research technologies sectors. The study pulls from SRS Acquiom's experience as a professional shareholder representative on 100+ structured life sciences deals involving almost 1,000 milestones potentially worth $30+ billion.
This is an invitation-only event. If you are interested in attending, please contact Alison Stephens.
Related contacts
This content is provided for general informational purposes only, and your access or use of the content does not create an attorney-client relationship between you or your organization and Cooley LLP, Cooley (UK) LLP, or any other affiliated practice or entity (collectively referred to as “Cooley”). By accessing this content, you agree that the information provided does not constitute legal or other professional advice. This content is not a substitute for obtaining legal advice from a qualified attorney licensed in your jurisdiction and you should not act or refrain from acting based on this content. This content may be changed without notice. It is not guaranteed to be complete, correct or up to date, and it may not reflect the most current legal developments. Prior results do not guarantee a similar outcome. Do not send any confidential information to Cooley, as we do not have any duty to keep any information you provide to us confidential. This content may be considered Attorney Advertising and is subject to our legal notices.